Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Sangamo Therapeutics's operating income for the twelve months ending Mar 31, 2026 was -$123.56M. For fiscal 2025 it was -$121.24M. The highest annual figure on record is -$19.40M in fiscal 2009.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$121.24M | – |
| FY2024 | Dec 31, 2024 | -$103.97M | – |
| FY2023 | Dec 31, 2023 | -$274.01M | – |
| FY2022 | Dec 31, 2022 | -$201.28M | – |
| FY2021 | Dec 31, 2021 | -$183.34M | – |
| FY2020 | Dec 31, 2020 | -$129.55M | – |
| FY2019 | Dec 31, 2019 | -$105.18M | – |
| FY2018 | Dec 31, 2018 | -$77.15M | – |
| FY2017 | Dec 31, 2017 | -$56.36M | – |
| FY2016 | Dec 31, 2016 | -$72.56M | – |
| FY2015 | Dec 31, 2015 | -$46.86M | – |
| FY2014 | Dec 31, 2014 | -$26.78M | – |
| FY2013 | Dec 31, 2013 | -$26.71M | – |
| FY2012 | Dec 31, 2012 | -$22.20M | – |
| FY2011 | Dec 31, 2011 | -$35.82M | – |
| FY2010 | Dec 31, 2010 | -$24.94M | – |
| FY2009 | Dec 31, 2009 | -$19.40M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$31.95M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.20M | – |
| Q3 FY2025 | Sep 30, 2025 | -$35.55M | -434.4% |
| Q2 FY2025 | Jun 30, 2025 | -$17.86M | – |
| Q1 FY2025 | Mar 31, 2025 | -$29.63M | – |
| Q4 FY2024 | Dec 31, 2024 | -$25.99M | – |
| Q3 FY2024 | Sep 30, 2024 | $10.63M | – |
| Q2 FY2024 | Jun 30, 2024 | -$37.08M | – |
| Q1 FY2024 | Mar 31, 2024 | -$51.53M | -385.7% |
| Q4 FY2023 | Dec 31, 2023 | -$62.06M | – |
| Q3 FY2023 | Sep 30, 2023 | -$106.41M | – |
| Q2 FY2023 | Jun 30, 2023 | -$123.57M | – |
| Q1 FY2023 | Mar 31, 2023 | $18.03M | – |
| Q4 FY2022 | Dec 31, 2022 | -$55.39M | – |
| Q3 FY2022 | Sep 30, 2022 | -$54.89M | – |
| Q2 FY2022 | Jun 30, 2022 | -$45.73M | – |
| Q1 FY2022 | Mar 31, 2022 | -$45.26M | – |
| Q4 FY2021 | Dec 31, 2021 | -$39.90M | – |
| Q3 FY2021 | Sep 30, 2021 | -$48.44M | – |
| Q2 FY2021 | Jun 30, 2021 | -$48.70M | – |
| Q1 FY2021 | Mar 31, 2021 | -$46.30M | – |
| Q4 FY2020 | Dec 31, 2020 | -$43.43M | -3056.6% |
| Q3 FY2020 | Sep 30, 2020 | -$3.70M | – |
| Q2 FY2020 | Jun 30, 2020 | -$37.90M | – |
| Q1 FY2020 | Mar 31, 2020 | -$44.52M | – |
| Q4 FY2019 | Dec 31, 2019 | $1.47M | – |
| Q3 FY2019 | Sep 30, 2019 | -$29.25M | – |
| Q2 FY2019 | Jun 30, 2019 | -$33.50M | – |
| Q1 FY2019 | Mar 31, 2019 | -$43.90M | – |
| Q4 FY2018 | Dec 31, 2018 | -$20.77M | – |
| Q3 FY2018 | Sep 30, 2018 | -$16.24M | – |
| Q2 FY2018 | Jun 30, 2018 | -$19.14M | – |
| Q1 FY2018 | Mar 31, 2018 | -$21.00M | – |
| Q4 FY2017 | Dec 31, 2017 | -$13.77M | – |
| Q3 FY2017 | Sep 30, 2017 | -$13.04M | – |
| Q2 FY2017 | Jun 30, 2017 | -$12.77M | – |
| Q1 FY2017 | Mar 31, 2017 | -$16.79M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.83M | – |
| Q3 FY2016 | Sep 30, 2016 | -$19.21M | – |
| Q2 FY2016 | Jun 30, 2016 | -$26.84M | – |
See a number that looks wrong?